Galileo Life Sciences (MDRM) Appoints New Vice President Of Corporate Development Glenn Vengroff

TORONTO, ON--(Marketwired - October 21, 2015) - Galileo Life Sciences, Inc. ('the Company") (OTC PINK: MDRM) announces that Glenn Vengroff has joined the company as Vice President, Corporate Development. Glenn is formerly Executive Vice President of an equity consulting firm in Toronto, Ontario, specializing in assisting early stage micro-cap to small-cap private companies to raise growth capital. Glenn played a key role in the successful launch of several publicly traded companies, initiated Investor awareness campaigns raising funds through stock sales and assisted and prepared company press releases, developed and marketed new products and assisted in Global export sales through international contacts.


GTIG is a Boutique IR company that specializes in designing and executing fully integrated Investor Relations, Communications and Corporate Strategy programs with the mission of helping clients achieve their goals while building visibility and establishing credibility. MDRM has instructed GTIG to develop a financing plan and oversee its implementation under the direct supervision of Mr. Vengroff who reports to Declan French, CEO of the company. The group will assist in the preparation of offerings of securities and registration statements on behalf of the Company and assist with preparation of all OTC filings to get the company in a fully reporting mode and raise funds. Mr. French expressed his satisfaction at finally putting communications with shareholders and investors at the forefront of the company's priorities and looks forward to issuing continuous updates on progress and direction.

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "pleased," "believe," "expects," "reflects," "aligned," "anticipates," "planned" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any initiatives will result in what the Company had originally intended. Any investment made into Galileo Life Sciences, Inc., would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the Company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the Company's financial reports and filings.

All Investor Relations queries in regard to GALILEO LIFE SCIENCES INC. (MDRM) should be directed to:

Glenn Vengroff
GTIG 1-289-275-0378
Galileo 1-416-642-2593